In the Dutch Melanoma Treatment Registry, the survival advantage to irAE was abrogated when anti-TNF is administered for steroid-refractory toxicity, mainly in the context of colitis (median overall survival 17 months in anti-TNF ± steroids versus 27 months in steroids only). Here, TNF is linked to colitis.